Compare RCAT & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCAT | CGEM |
|---|---|---|
| Founded | 2002 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Wholesale Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2017 | 2020 |
| Metric | RCAT | CGEM |
|---|---|---|
| Price | $8.24 | $16.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $20.00 | ★ $30.13 |
| AVG Volume (30 Days) | ★ 7.0M | 548.5K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $17,836,382.00 | N/A |
| Revenue This Year | $271.60 | N/A |
| Revenue Next Year | $41.21 | $5.20 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 79.95 | N/A |
| 52 Week Low | $5.77 | $5.68 |
| 52 Week High | $18.78 | $19.43 |
| Indicator | RCAT | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 44.72 | 43.65 |
| Support Level | $7.31 | $16.00 |
| Resistance Level | $8.85 | $19.10 |
| Average True Range (ATR) | 0.58 | 0.95 |
| MACD | 0.07 | -0.22 |
| Stochastic Oscillator | 54.78 | 16.81 |
Red Cat Holdings Inc is a drone technology company integrating robotic hardware and software for military, government, and commercial operations. Its suite of solutions includes the Arachnid family of ISR and precision strike drones, which includes the Black Widow, a small unmanned ISR system; and WEB (Warfighter Electronic Bridge) GCS, designed to command and control an entire drone family of systems for military operations. Its other offerings include Edge 130 Blue drone systems, Trichon, a fixed-wing VTOL for extended endurance and range, and FANG FPV drones optimized for military operations with precision strike capabilities. The firm's Division includes Teal, FlightWave, and Blue Ops.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.